July 22 (Reuters) - Irras AB IRRAS.ST :
* Q2 NET REVENUE AMOUNTED TO SEK 9.7 MILLION (5.1)
* Q2 OPERATING LOSS (EBIT) AMOUNTED TO SEK 35.8 MILLION
(LOSS
26.7)
* FINANCIAL TARGETS: REVENUE IS EXPECTED TO EXCEED MSEK 350
IN
2025 WITH A GROSS MARGIN ABOVE 60 PERCENT. CASHFLOW BREAKEVEN IS
EXPECTED BY 2025
* IN 2022, REVENUES ARE EXPECTED TO EXCEED MSEK 35 WITH A
GROSS
MARGIN ABOVE 30 PERCENT.
* COMPANY MAY CONSIDER A CHANGE IN ITS COMMERCIAL STRATEGY
BY
EXPLORING POTENTIAL PARTNERSHIPS WITH ESTABLISHED MEDICAL DEVICE
COMPANIES TO ACCELERATE ROLLOUT OF ITS PRODUCTS.
Source text for Eikon: ID:nWkr3mRtrY
Further company coverage: IRRAS.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))